Why the study?
Does pulmonary resection or regional chemotherapy improve survival in patients with pulmonary metastasis from osteogenic sarcoma compared to no treatment or radiation?
Does pulmonary resection or regional chemotherapy improve survival in patients with pulmonary metastasis from osteogenic sarcoma compared to no treatment or radiation?
Pulmonary resection and regional chemotherapy offer survival benefits over no treatment or radiation for pulmonary metastases from osteogenic sarcoma.
May support resection in select cases of pulmonary metastases from osteogenic sarcoma; leaves open need for randomized confirmation.
The patient of osteogenic sarcoma develops pulmonary metastasis with high incidence. To estimate the duration of a given tumor and the time of inception, we calculated retrospectively the growth rate of tumor. If the growth rate of tumor before treatment is assumed to be constant, the majority of patients of osteogenic sarcoma had already developed pulmonary metastasis when symptoms from primary tumor appeared. Patients who are diagnosed as osteogenic sarcoma should be treated for pulmonary metastasis as well as for primary tumor even if there is no abnormal density on the chest roentgenogram.Bronchial artery or pulmonary artery infusion using anticancer agents for osteogenic sarcoma without visible metastasis on the chest roentgenogram is a treatment of choice.
No takes yet. Share an insight, caveat, or question.
Ishihara et al. (1971) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: